---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009248"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:27:49.903873+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA Q1 net loss $19.7M; cash $110M; milestones from Roche and Gilead; Phase 2 data on track for Q2 2023

## Summary
- Q1 net loss $19.7M vs $18.0M YoY; revenue $3.2M (up from $1.4M) on higher collaboration recognition.
- Cash $110.0M at March 31, 2023, down from $113.4M at Dec 31, 2022; used in operations partly offset by collaboration funds.
- Achieved $10M milestone from Roche for HB-700 (KRAS-mutated cancers) and $5M from Gilead for HB-400 (chronic hepatitis B).
- Phase 2 data for HB-200 in HPV16+ head and neck cancer with pembrolizumab expected in Q2 2023; Phase 1 trials initiated for HB-300 and HB-400.
- Appointed Terry Coelho to Board of Directors; preclinical data presented at AACR on arenaviral combo with Roche's PD1-IL2v.

## SEC filing metadata
- accession: 0001558370-23-009248
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837023009248/0001558370-23-009248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837023009248/hook-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009248
- JSON: https://secwatch.observer/filing/0001558370-23-009248.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009248.txt

## Key facts
- Earnings Releases
  HOOKIPA Pharma Inc. reported First Quarter 2023 results: revenue $3.2 million, net income $19.7 million.
  - Period: First Quarter 2023
  - Revenue: $3.2 million
  - Net income: $19.7 million
  - Result: reported results
  source text: Revenue was $3.2 million for the three months ended March 31, 2023 compared to $1.4 million for the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000155837023009248/0001558370-23-009248-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.